Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer’s disease: a prospective, open-label pilot study

Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer’s disease: a prospective, open-label pilot study

Tohru Ohnuma, Aiko Toda, Ayako Kimoto, Yuto Takebayashi, Ryoko Higashiyama, Yuko Tagata, Masanobu Ito, Tsuneyoshi Ota, Nobuto Shibata, Heii Arai Department of Psychiatry, Juntendo University Alzheimer’s Disease Project, Faculty of Medicine, Juntendo University, Tokyo, Japan Objectives: T...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ohnuma T, Toda A, Kimoto A, Takebayashi Y, Higashiyama R, Tagata Y, Ito M, Ota T, Shibata N, Arai H
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2016
Materias:
Alzheimer’s disease
medium-chain triglycerides
ketone
cognitive function
apolipoprotein E epsilon 4
Geriatrics
RC952-954.6
Acceso en línea:https://doaj.org/article/12bc6bb150c34f9fb73a2b8c63119f4b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:12bc6bb150c34f9fb73a2b8c63119f4b
record_format dspace
spelling oai:doaj.org-article:12bc6bb150c34f9fb73a2b8c63119f4b2021-12-02T04:05:26ZBenefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer’s disease: a prospective, open-label pilot study1178-1998https://doaj.org/article/12bc6bb150c34f9fb73a2b8c63119f4b2016-01-01T00:00:00Zhttps://www.dovepress.com/benefits-of-use-and-tolerance-of-medium-chain-triglyceride-medical-foo-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Tohru Ohnuma, Aiko Toda, Ayako Kimoto, Yuto Takebayashi, Ryoko Higashiyama, Yuko Tagata, Masanobu Ito, Tsuneyoshi Ota, Nobuto Shibata, Heii Arai Department of Psychiatry, Juntendo University Alzheimer’s Disease Project, Faculty of Medicine, Juntendo University, Tokyo, Japan Objectives: This is the first clinical trial of this type in Japan, designed to analyze two important aspects of Alzheimer’s disease (AD) management using medium-chain triglycerides. Axona was administered for 3 months (40 g of powder containing 20 g of caprylic triglycerides). We used an indurating, four-step dose-titration method (from 10 to 40 g per day) for 7 days before the trial, and examined the tolerance and adverse effects of this intervention. We also investigated its effect on cognitive function in mild-to-moderate AD patients.Patients and methods: This was a clinical intervention in 22 Japanese patients with sporadic AD at a mild-to-moderate stage (ten females, 12 males), mean age (± standard deviation) 63.9 (±8.5) years, Mini-Mental State Examination (MMSE) score, 10–25, seven patients were ApoE4-positive. During Axona administration, we examined changes in cognitive function by obtaining MMSE and AD assessment-scale scores. Intolerance and serum ketone concentrations were also examined.Results: The tolerance of Axona was good, without severe gastrointestinal adverse effects. Axona did not improve cognitive function in our sample of AD patients, even in those patients without the ApoE4 allele. However, some ApoE4-negative patients with baseline MMSE score ≥14 showed improvement in their cognitive functions.Conclusion: The modified dose-titration method, starting with a low dose of Axona, decreased gastrointestinal adverse effects in Japanese patients. Axona might be effective for some relatively mildly affected patients with AD (with cognitive function MMSE score of ≥14 and lacking the ApoE4 allele). Keywords: Alzheimer’s disease, medium-chain triglycerides, ketone, cognitive function, apolipoprotein E epsilon 4Ohnuma TToda AKimoto ATakebayashi YHigashiyama RTagata YIto MOta TShibata NArai HDove Medical PressarticleAlzheimer’s diseasemedium-chain triglyceridesketonecognitive functionapolipoprotein E epsilon 4GeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 11, Pp 29-36 (2016)
institution DOAJ
collection DOAJ
language EN
topic Alzheimer’s disease
medium-chain triglycerides
ketone
cognitive function
apolipoprotein E epsilon 4
Geriatrics
RC952-954.6
spellingShingle Alzheimer’s disease
medium-chain triglycerides
ketone
cognitive function
apolipoprotein E epsilon 4
Geriatrics
RC952-954.6
Ohnuma T
Toda A
Kimoto A
Takebayashi Y
Higashiyama R
Tagata Y
Ito M
Ota T
Shibata N
Arai H
Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer’s disease: a prospective, open-label pilot study
description Tohru Ohnuma, Aiko Toda, Ayako Kimoto, Yuto Takebayashi, Ryoko Higashiyama, Yuko Tagata, Masanobu Ito, Tsuneyoshi Ota, Nobuto Shibata, Heii Arai Department of Psychiatry, Juntendo University Alzheimer’s Disease Project, Faculty of Medicine, Juntendo University, Tokyo, Japan Objectives: This is the first clinical trial of this type in Japan, designed to analyze two important aspects of Alzheimer’s disease (AD) management using medium-chain triglycerides. Axona was administered for 3 months (40 g of powder containing 20 g of caprylic triglycerides). We used an indurating, four-step dose-titration method (from 10 to 40 g per day) for 7 days before the trial, and examined the tolerance and adverse effects of this intervention. We also investigated its effect on cognitive function in mild-to-moderate AD patients.Patients and methods: This was a clinical intervention in 22 Japanese patients with sporadic AD at a mild-to-moderate stage (ten females, 12 males), mean age (± standard deviation) 63.9 (±8.5) years, Mini-Mental State Examination (MMSE) score, 10–25, seven patients were ApoE4-positive. During Axona administration, we examined changes in cognitive function by obtaining MMSE and AD assessment-scale scores. Intolerance and serum ketone concentrations were also examined.Results: The tolerance of Axona was good, without severe gastrointestinal adverse effects. Axona did not improve cognitive function in our sample of AD patients, even in those patients without the ApoE4 allele. However, some ApoE4-negative patients with baseline MMSE score ≥14 showed improvement in their cognitive functions.Conclusion: The modified dose-titration method, starting with a low dose of Axona, decreased gastrointestinal adverse effects in Japanese patients. Axona might be effective for some relatively mildly affected patients with AD (with cognitive function MMSE score of ≥14 and lacking the ApoE4 allele). Keywords: Alzheimer’s disease, medium-chain triglycerides, ketone, cognitive function, apolipoprotein E epsilon 4
format article
author Ohnuma T
Toda A
Kimoto A
Takebayashi Y
Higashiyama R
Tagata Y
Ito M
Ota T
Shibata N
Arai H
author_facet Ohnuma T
Toda A
Kimoto A
Takebayashi Y
Higashiyama R
Tagata Y
Ito M
Ota T
Shibata N
Arai H
author_sort Ohnuma T
title Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer’s disease: a prospective, open-label pilot study
title_short Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer’s disease: a prospective, open-label pilot study
title_full Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer’s disease: a prospective, open-label pilot study
title_fullStr Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer’s disease: a prospective, open-label pilot study
title_full_unstemmed Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer’s disease: a prospective, open-label pilot study
title_sort benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of japanese patients with alzheimer’s disease: a prospective, open-label pilot study
publisher Dove Medical Press
publishDate 2016
url https://doaj.org/article/12bc6bb150c34f9fb73a2b8c63119f4b
work_keys_str_mv AT ohnumat benefitsofuseandtoleranceofmediumchaintriglyceridemedicalfoodinthemanagementofjapanesepatientswithalzheimerrsquosdiseaseanbspprospectiveopenlabelpilotstudy
AT todaa benefitsofuseandtoleranceofmediumchaintriglyceridemedicalfoodinthemanagementofjapanesepatientswithalzheimerrsquosdiseaseanbspprospectiveopenlabelpilotstudy
AT kimotoa benefitsofuseandtoleranceofmediumchaintriglyceridemedicalfoodinthemanagementofjapanesepatientswithalzheimerrsquosdiseaseanbspprospectiveopenlabelpilotstudy
AT takebayashiy benefitsofuseandtoleranceofmediumchaintriglyceridemedicalfoodinthemanagementofjapanesepatientswithalzheimerrsquosdiseaseanbspprospectiveopenlabelpilotstudy
AT higashiyamar benefitsofuseandtoleranceofmediumchaintriglyceridemedicalfoodinthemanagementofjapanesepatientswithalzheimerrsquosdiseaseanbspprospectiveopenlabelpilotstudy
AT tagatay benefitsofuseandtoleranceofmediumchaintriglyceridemedicalfoodinthemanagementofjapanesepatientswithalzheimerrsquosdiseaseanbspprospectiveopenlabelpilotstudy
AT itom benefitsofuseandtoleranceofmediumchaintriglyceridemedicalfoodinthemanagementofjapanesepatientswithalzheimerrsquosdiseaseanbspprospectiveopenlabelpilotstudy
AT otat benefitsofuseandtoleranceofmediumchaintriglyceridemedicalfoodinthemanagementofjapanesepatientswithalzheimerrsquosdiseaseanbspprospectiveopenlabelpilotstudy
AT shibatan benefitsofuseandtoleranceofmediumchaintriglyceridemedicalfoodinthemanagementofjapanesepatientswithalzheimerrsquosdiseaseanbspprospectiveopenlabelpilotstudy
AT araih benefitsofuseandtoleranceofmediumchaintriglyceridemedicalfoodinthemanagementofjapanesepatientswithalzheimerrsquosdiseaseanbspprospectiveopenlabelpilotstudy
_version_ 1718401412913692672

Ejemplares similares